Moderna CEO outlines next steps after melanoma vaccine trial success

Moderna CEO on what's next after success in cancer vaccine

STAT • 26 Հոկ 08:31

Moderna's chief executive Stéphane Bancel highlighted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran and outlined its implications for the company's research direction.

World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

ScienceAlert • 26 Հոկ 02:01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show

The Globe and Mail • 25 Հոկ 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

What's next for cancer vaccines after successful melanoma study

STAT • 25 Հոկ 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

NBC News • 23 Հոկ 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive • 22 Հոկ 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica • 22 Հոկ 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.